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Summary 14 
Diagnostic records are a key feature of any cancer epidemiology, prevention or 15 
control strategy for both human beings and animals. Thus, the information stored in 16 
human and animal cancer registries is essential to comparative epidemiologic, 17 
pathogenic and therapeutic research.  18 
This study presents the Swiss Canine Cancer Registry, compiled between 1955 and 19 
2008. The data consists of pathology diagnostic records issued by three veterinary 20 
diagnostic laboratories in Switzerland. The tumours are classified according to the 21 
International Classification of Oncology for Humans (ICD-O-3) guidelines: tumour 22 
type, malignancy and body location (WHO, 2013). The dogs are classified according 23 
to breed, age, sex, castration status and place of residence.  24 
The diagnostic data were correlated to the relative dog population and the 25 
occurrence of cancer in dogs was thus investigated. In 121,963 canine patients 26 
67,943 tumours were diagnosed. 47.07% of which were malignant tumours. The 27 
most common tumour location was the skin (37.05%), followed by mammary glands 28 
(23.55%) and soft tissue (13.66%). The most common tumour diagnoses were 29 
epithelial (38.45%), mesenchymal (35.10%) and lymphatic tumours (13.23%). 30 
The results are compared with other canine registries. Similarities to tumour 31 
distribution and incidence in other findings are listed and specific difficulties in 32 
comparison are pointed out. We hope that this study will mark the beginning of a 33 
continuous registration of dog tumours in Switzerland, which, in turn, will serve as a 34 
reference for research in the fields of animal and human oncology. 35 
 36 
Keywords: canine, cancer, registry, epidemiology, tumour 37 
  38 
  3
Introduction  39 
Cancer is a leading cause of death in both humans and dogs (Pinho et al., 2012). 40 
However, current medical research is hampered by the complex biology of the 41 
disease. Murine cancer models are highly standardised experiments which have 42 
contributed tremendously to knowledge about cancer mechanisms and treatment 43 
regimes. Nonetheless, murine cancer models are frequently limited in representing 44 
specific aspects of spontaneous human cancer such as long time latency, recurrence 45 
and metastasis (Porello et al., 2006; Thamm and Dow, 2009; Martić-Kehl et al., 2012; 46 
Ranieri et al., 2013). 47 
To fill in the knowledge gaps of spontaneous cancer models, cancer registries 48 
provide a key to the epidemiology of cancer over space and time. In many industrial 49 
countries, human cancer registration has been an established practice since the 50 
1940s (Brønden et al., 2007). Companion animal cancer registries were introduced in 51 
the 1960s, following increasing mortality due to spontaneous tumours. The study of 52 
companion animal tumours offers several benefits not only for animal epidemiology 53 
but also for comparative epidemiologic, pathogenic and therapeutic research. 54 
Companion animals have a functioning immune system and a length of life span that 55 
allow them to develop tumours resembling human tumours in morphology and 56 
behaviour. Companion animals also benefit from oncologic therapies that are 57 
commonly applied to humans. Companion animals share the same habitat conditions 58 
as their caregivers and can thus indicate environmental hazards (Bukowski and 59 
Wartenberg, 1997; Backer et al., 2001; Gamlen et al., 2008; Marconato et al., 2009; 60 
Bettini et al., 2010). Companion animals, and dogs in particular, share significantly 61 
more genes with humans than do rodents (Pinho et al., 2012). Therefore 62 
investigations of spontaneous dog cancer can provide a partial alternative to animal 63 
testing (Bukowski and Wartenberg, 1997; Thamm and Dow, 2009). 64 
In the 1960s and 1970s three population-based animal registries were completed in 65 
the USA: the California Animal Neoplasm Registry (1963 - 1966) (Dorn, 1968), the 66 
Kansas University Neoplasm Registry (1961 - 1971) (Strafuss, 1976) and the Tulsa 67 
Registry of Canine and Feline Neoplasms (1972 - 1977) (MacVean et al., 1978). 68 
Since the late 1980s several animal cancer registries have been established and are 69 
still being updated: the Purdue Comparative Oncology Program (since 1979) (Purdue 70 
Comparative Oncology Program, 2006), the Cancer Registry and Surveillance 71 
System for Companion Animals, Cornell (since 1980) (Page, 2004), the Animal 72 
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Tumour Registry of Genoa (since 1985) (Merlo et al., 2008), the Norwegian Cancer 73 
Project (since 1990) (Gamlen et al., 2008), the VetCancer Registry (since 1994) 74 
(Brønden et al., 2007), the Registry on Canine Tumours in Sweden/Agria (since 75 
1995) (Egenvall et al., 2011), the Danish Veterinary Cancer Registry (since 2005) 76 
(Brønden et al., 2010), the Animal Tumour Registry of the Vicenza and Venice 77 
provinces (since 2009) (Vascellari et al., 2009) and the Guelph Companion Animal 78 
Cancer Epidemiologic Registry (since 2010) (Nødtvedt et al., 2011). 79 
The Swiss Canine Cancer Registry (1955 - 2008) has been assembled as part of the 80 
project “One Medicine - One Oncology: Incidence and geographic distribution of 81 
companion animal cancer in Switzerland 1955 - 2008”. Additionally, the project 82 
benefits from information about the population at risk, since the chipping and 83 
registration of dogs in Switzerland has been compulsory since 2006. The dog 84 
population was surveyed with an accuracy reaching 95% in 2008 (personal 85 
information, Gesellschaft für Schweizer Tierärzte, the Swiss Society of 86 
Veterinarians). These latest data, together with data originating from previous 87 
research on the dog population, allows linking our results to the total population of 88 
dogs in Switzerland (Pospischil et al., 2013). 89 
The aim of this paper is to present the Swiss Canine Cancer Registry, which was 90 
compiled between 1955 and 2008. Data consists of pathology diagnostic records 91 
issued by three veterinary diagnostic laboratories in Switzerland. The tumours are 92 
classified according to the International Classification of Oncology for Humans (ICD-93 
O-3) guidelines: tumour type, malignancy and body location (WHO, 2013). The dogs 94 
are classified according to breed, age, sex, castration status and place of residence. 95 
The analysis provides a retrospective overview of the frequency of malignant and 96 
benign neoplasms. We also relate these findings to the general dog population and 97 
characterize the distribution of tumours by type, behaviour, body location, age and 98 
diagnostic method. 99 
  100 
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Material and methods 101 
Data source 102 
This study is based on a dog tumour registry comprising 121,963 diagnostic records 103 
of dog patients provided by three veterinary diagnostic laboratories in Switzerland: 104 
the Vetsuisse Faculty Institut für Veterinärpathologie Zürich (IVPZ), Institut für 105 
Tierpathologie Bern (ITP) and the Zyto-Histo Diagnostics private veterinary 106 
diagnostic laboratory (based in Rorbas Freienstein).  107 
IVPZ (1955 – 2008): Three sets of diagnostic records (n=97,759) from canine post-108 
mortem, biopsy and cytology samples. The sets originate from three time periods: 109 
• IVPZ-GL (1955 - 1964): Set of diagnostic records (n=3,797) from canine post-110 
mortem samples. The records were originally handwritten documents and later 111 
digitized in an Excel file.  112 
• IVPZ-SLK (1964 - 1988): Set of diagnostic records (n=33,100) from canine 113 
post-mortem and biopsy samples. The records were transcribed to punch 114 
cards using diagnostic key words (Keydex, Fa. Royal McBee; Stünzi and Lott-115 
Stolz, 1967). These records were digitized by Scydoc, an external company 116 
based in Zug, Switzerland. The results were crosschecked using the original 117 
typed reports. 118 
• IVPZ-APPX (1987 - 2008): Set of diagnostic records (n=60,862) from canine 119 
post-mortem, biopsy and cytology samples. The records were stored in the 120 
electronic patient record system of the IVPZ. In 1987 when the digitized 121 
collection of data started, the punch cards were still used. There was no 122 
overlapping of data since patients were only recorded in one of the systems.  123 
ITP (1983 - 2008): Set of diagnostic records (n=20,674 ) from canine post-mortem 124 
and biopsy samples. 125 
Zyto-Histo Diagnostics (2007 - 2008) Set of diagnostic records (n=3,530) from canine 126 
biopsy samples. 127 
The samples from the IVPZ, ITP and Zyto-Histo Diagnostics were examined by 128 
histopathology. 129 
Data preparation  130 
The data sets were compiled in a FileMaker database, which was exported into a 131 
Stata database. Individual diagnostic records were standardized according to age, 132 
sex, castration status and breed. The diagnoses were then coded according to the 133 
tumour topographic and morphologic keys of the ICD-O-3 (Table 1 and Table 2) and 134 
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checked for plausibility using the original patient records. All tumour diagnoses were 135 
confirmed by histopathology. Epidermal cysts were excluded. Diagnoses were 136 
grouped for future comparison with human cancer and for this reason some of these 137 
groups may be unusual for veterinarians. The groups are described in Table 3. The 138 
term “epithelial tumour” is used in two different ways: first as an overall group 139 
including all types of epithelial tumour and then as a narrow group: “epithelial* 140 
tumour” (Table 3).  141 
Tumour groups included malignant and benign tumours, e.g. adenoma and 142 
adenocarcinoma were categorized as one group “adenoma, adenocarcinoma”. Each 143 
diagnostic record shows information about the tumour malignancy grade in an 144 
additional field. To investigate the malignancy, the tumour group was divided into 145 
“benign” (malignancy grade 0 - 2) and “malignant” (malignancy grade 3 - 6) according 146 
to the ICD-O-3 classification. Because benign tumours can develop into malignant 147 
tumours of the same type, we did not treat tumours such as adenoma and 148 
adenocarcinoma as separate groups. The same procedure was applied to coupled 149 
tumour groups, like lymphangioma and lymphangiosarcoma, osteoma and 150 
osteosarcoma, naevi and melanoma, myxoma and myxosarcoma. As different 151 
pathologists had worked on the diagnostics, we encountered two different 152 
approaches to specifying the location of fibrosarcomas in the subcutaneous tissue. 153 
Some pathologists used “skin” as the location because of the skin biopsy. Other 154 
pathologists used “soft tissue” as the origin of the tumours. We conflated these two 155 
locations and recoded “skin” as “soft tissue” for fibrosarcomas. 156 
Breed allocation is based on information available in the diagnostic records. A 157 
declaration of one or two mixed breeds is categorized according to the first breed. A 158 
non-specific allocation as mixed breed, bastard or crossbreed is categorized under 159 
crossbreed. The 17 most common breeds, each one comprised of more than 900 160 
individuals, were further investigated. The remaining breeds and the diagnostic 161 
records with unknown breeds were listed as "Other breeds". The breed category 162 
Shepherd includes German Shepherd, Beauceron Berger de Beauce, White 163 
Shepherd, Berger de Picardie, Berger de Savoie, Berger des Pyrénées, 164 
Groenendael, Laekenois, Malinois, Tervueren. 165 
Diagnostic records for dogs residing outside Switzerland were excluded from the 166 
analysis.  167 
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Results 168 
Dataset 169 
A total of 121,963 dogs were examined through histopathology, of which 63,214 170 
(51.83%) were diagnosed with tumour lesions. Of those, 59,124 (93.53%) had 171 
developed a single tumour and 4,090 (6.47%) had developed multiple tumours. 172 
Furthermore, 35,232 (52.93%) of the tumours were benign and 31,336 (47.07%) 173 
malignant. The proportion of tumour bearing patients versus patients without a 174 
tumour lesion differed according to the method of examination: in biopsy 175 
histopathology 64.81% of the patients were diagnosed with a tumour lesion, in 176 
cytological examinations 41.96% and in post-mortem examinations 31.04%.  177 
 178 
Breed distribution  179 
Our data set refers to 182 different dog breeds (n=101,281), a large number of 180 
crossbreeds (n= 12,193) and some unclassified breeds (n=8,489). The most frequent 181 
breed was the Shepherd dog (10.13%), closely followed by Crossbreeds (10.00%) 182 
and Retriever (9.37%) (Table 4). 183 
 184 
Incidence rates  185 
Figure 1 shows the influence of the examination methods on the annual tumour 186 
incidence rate. Post-mortem examination had a relatively stable annual incidence 187 
rate: 13 cases of neoplasia per 100,000 dogs in 1955 and 20 cases in 2008. A peak 188 
of 65 cases per 100,000 dogs was observed in the 1980s. Conversely, the overall 189 
annual tumour incidence rate rose from 13 cases of neoplasia per 100,000 dogs in 190 
1955 to 695 cases in 2008. This trend is comparable with the rise of the incidence 191 
rate of biopsy and cytology cases, which increased from 141 cases of neoplasia per 192 
100,000 dogs in 1968 to 675 cases in 2008. 193 
 194 
Distribution of the most common diagnoses 195 
The most common tumours were epithelial (38.45%), mesenchymal (35.1%), 196 
lymphatic (13.23%), melanoma (3.90%), skeletal (1.74%) and special gonadal 197 
neoplasia (1.57%). Figure 2 presents a more detailed distribution of diagnoses, with 198 
adenoma and adenocarcinoma (32.62%) at the top. 199 
The most prevalent diagnoses over time (1955 – 2008) 200 
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The proportion of epithelial tumours declined from 45.65% in 1955 to 34.46% in 201 
2008, whereas the proportions of mesenchymal and lymphatic tumours, melanoma 202 
and special gonadal neoplasia rose. Mesenchymal tumours rose from 28.26% in 203 
1955 to 34.36% in 2008, lymphatic tumours from 8.70% to 14.69%, melanoma from 204 
0.00% to 5.18% and special gonadal neoplasia from 0.00% to 2.47% (Figure 2). 205 
  206 
Malignancy of the most common tumour diagnoses 207 
Of total tumours, 47.07%  were malignant. The following tumour groups had 208 
malignancy rates higher than the overall rate: skeletal tumours (96.61%), melanoma 209 
(87.21%), gonadal germ cell tumours (86.38%), epithelial tumour (56.52%), lymphatic 210 
tumour (52.79%). The following tumour groups had malignancy rates lower than the 211 
overall rate: neural tumours (43.38%), unclassified neoplasms (32.6%), 212 
mesenchymal tumours (29.65%), lymphangioma and lymphangiosarcoma (16.09%), 213 
special gonadal neoplasia (8.15%) and odontogenic neoplasia (2.67%). Figure 4 214 
presents the malignancy rate of the most frequently occurring tumour groups.  215 
A more accurate grouping shows that the following tumour groups had malignancy 216 
rates higher than the overall rate: mesothelial neoplasia (100%), complex epithelial 217 
neoplasia (99.47%), leukaemia (99.39%), transitional cell papilloma, transitional cell 218 
carcinoma (98.21%), other neoplasia of bones (96.45%), osteoma and osteosarcoma 219 
(95.49%), glial neoplasia (94.26%), epithelial* tumour (89.97%), soft tissue sarcoma 220 
(88.24%), naevi and melanoma (87.21%), gonadal germ cell tumour (86.38%), 221 
myxoma and myxosarcoma (83.24%), plasma cell neoplasia (82.44%), synovia like 222 
neoplasia (53.49%), histiocytic neoplasia (52.13%), adenoma and adenocarcinoma 223 
(50.79%), paraganglioma (48.5%). 224 
Location of tumours 225 
Most of the neoplasms were located in the skin (32.29%), the mammary gland 226 
(20.53%) and the soft tissue (11.90%). Figure 5 shows that the frequency of tumours 227 
in all other locations was below 10%. The tumour locations in post-mortem samples 228 
were more balanced than in the overall data and the ranking was different (Figure 6). 229 
The gastrointestinal tract (11.40%) and the respiratory system (10.63%) were the 230 
leading tumour locations. The largest variety of tumour types was found in the mouth 231 
and the pharynx, where seven different tumour types were identified (Figure7). 232 
Age distribution  233 
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The age distribution of canine patients (Figure 8) shows that most patients, 234 
irrespective of tumour presence, were between five and ten years old (48.79%). 235 
Another large group consisted of dogs older than ten years of age (21.42%). Only 236 
16.80% were between one and five years old, and the group of under one year old 237 
dogs (6.84%) mainly consisted of patients without tumours. 238 
  239 
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Discussion 240 
To our knowledge, the figures of 121,963 canine patients and 67,943 tumour 241 
diagnoses collected over 53 years renders the Swiss Canine Cancer Registry the 242 
most comprehensive animal cancer registry at a national level. However, there are 243 
some shortcomings, which are typical of long-term retrospective studies. One such 244 
issue is that diagnoses were made by different pathologists at different time periods. 245 
The criteria for certain diagnoses may have changed over time and in some cases 246 
there may be a subjective factor in histopathologic diagnostics. This problem was 247 
overcome by restricting data evaluation to such tumour entities as could be clearly 248 
identified and have been known for a long time. 249 
The yearly distribution of breeds in the Swiss Canine Cancer Registry reflects the 250 
change in various breeds’ fashion in the Swiss dog population, as described by 251 
Pospischil et al. (2013). In the 1950s and 1960s Poodle (13.80%), Shepherd 252 
(12.66%), Crossbreed (10.61%), Boxer (9.75%) and Dachshund (9.69%) were the 253 
most common breeds. From 1970 to 2008 the most common breeds were 254 
Crossbreed (10%), Retriever (9.97%), Shepherd (9.87%) and Swiss Mountain Dog 255 
(6.53%). 256 
During the study period, the Swiss dog population increased constantly and the 257 
relative tumour incidence rose dramatically, from 13 cases per 100,000 dogs at risk 258 
in 1955 to 695 in 2008. This trend could be explained by selection bias, due to the 259 
availability of new diagnostic methods, namely biopsies (since 1968) and fine needle 260 
aspirations (since 1991). We also suppose that this trend may be influenced by a 261 
rising prevalence of tumours in dogs. In fact, similarly to humans, dogs’ life 262 
expectancy has risen constantly since 1955, due to advancements in veterinary 263 
medicine. An increased life expectancy, however, makes dogs more susceptible to 264 
tumours, since tumours tend to develop at an older age (Bonnet and Egenvall, 2010).  265 
On the other hand, the tumour incidence rate in post-mortem samples did not 266 
increase over time. This might at least partly be explained by the decreasing relative 267 
number of post-mortem investigations, as dog owners tend to refuse a post-mortem 268 
examination for affective reasons. Moreover, since the introduction of biopsy, 269 
tumours may have been diagnosed before death, so that a post-mortem investigation 270 
was no longer necessary.  271 
Additional factors that may have contributed to the increasing canine tumour 272 
incidence rate in Switzerland are the following. First, the change in dogs’ role in 273 
society from working dogs to family members, fully entitled to veterinary care, 274 
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diagnostic examinations and therapeutic intervention. Second, the standard of living 275 
has generally risen over the years and dog owners can afford systematic diagnostic 276 
examinations. Third, the density of licensed veterinary practices increased from 2 277 
practises per 100,000 dogs to 346 practises per 100,000 dogs in Switzerland, 278 
between 1955 and 2008 (personal information, Gesellschaft für Schweizer 279 
Tierärztinnen und Tierärzte, the Swiss Society of Veterinarians), democratizing 280 
veterinary care over the whole country. Fourth, the evolution of environmental risk 281 
factors (e.g. UV radiation or air pollution) may have encouraged tumour development 282 
(Porello et al., 2006; Reif and Cohen, 1979). Environmental factors responsible for 283 
dog tumours are topics to be investigated in future research. 284 
It is generally difficult to compare tumour incidences between animal cancer 285 
registries, because of differences in the sampling methods (MacVean et al., 1978; 286 
Brønden et al., 2007; Vascellari et al., 2009; Egenvall et al., 2011; Brønden et al., 287 
2010). In order to estimate the population at risk, a telephone survey was undertaken 288 
in Northern Italy (Vascellari et al., 2009). Data were collected from an animal health 289 
insurance company (Agria) in Sweden (Egenvall et al., 2011) or by counting the 290 
“veterinarian-using” dogs in Tulsa, USA (MacVean et al., 1978)) and by legally 291 
regulated dog registration in Denmark in the Danish Dog Registry (Brønden et al., 292 
2010) and, since 2006, in Switzerland. 293 
However, in Switzerland, the tumour incidence rate for 2008, which reached a value 294 
of 695 cases per 100,000 dogs, lies in a position midway between the rates of other 295 
countries. For example, 282 cases per 100,000 dogs were observed in Northern Italy 296 
(Vascellari et al., 2009), 500 cases per 100,000 dogs in Sweden (Egenvall et al., 297 
2005), 748 cases per 100,000 dogs in the UK (Dobson et al, 2002) and 1,416 298 
tumours per 100,000 dogs in Tulsa, USA (MacVean et al., 1978). The observed 299 
malignancy distribution (47.07%) is similar to that of other cancer registries. It was 300 
reported as 38% by Brønden et al. (2010), 50% by Gamlen et al. (2008), 49% by 301 
Merlo et al. (2008) and 51% by Vascellari et al. (2009). 302 
Skeletal tumours and melanoma showed the highest malignancy, with 96.61% and 303 
87.21%, respectively. These figures are also similar to the results reported by Porello 304 
et al. (2006) and Ehrhart et al. (2013). Skin (32.29%), the mammary gland (20.53%) 305 
and soft tissues (11.90%) are the most frequent tumour locations, as confirmed by 306 
Dobberstein (1937), Mulligan (1949), Dorn (1967), MacVean et al. (1978), Bastianello 307 
(1983), Arnesen et al. (2001), Dobson et al. (2002), Gamlen et al. (2008), Vascellari 308 
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et al. (2009) and Dobson (2013). These results are certainly influenced by the fact 309 
that both locations are easy to access and to observe, both for the dog’s owner and 310 
the veterinarian. 311 
The ranking of the tumour locations diagnosed in post-mortem investigations shows 312 
the highest values for the gastrointestinal tract (14.23%) and the respiratory system 313 
(10.63), including intrathoracal organs (13.28%). In the ranking of all tumours 314 
sampled through post-mortem and biopsy, the gastrointestinal tract (7.49%) and the 315 
respiratory system, including intrathoracal organs (2.09%) hold places four and six, 316 
respectively, similarly to the observations of Dobson et al. (2002), Porello et al. 317 
(2006) Vascellari et al. (2009) and Dobson (2013). The different frequencies in post-318 
mortem samples and samples from biopsy suggest an over-reporting of tumours at 319 
easily accessible locations, together with an underestimation of impenetrable 320 
locations. 321 
The male sexual organs rank fifth (4.43%) in all examination methods and seventh 322 
(8.45%) in the post-mortem samples. Both results demonstrate that differences 323 
depend on the method of investigation and are similar to the findings of Dobberstein 324 
(1953), Mulligan (1949), Dorn (1967) and Bastianello (1983). Vascellari et al. (2009) 325 
observe that 13.4% tumours were found in the male genital tract. In the Norwegian 326 
Canine Cancer Registry, tumours in the testes (2.4%) were less frequent than in the 327 
oral cavity (3.7%) (Gamlen et al., 2008), which is an interesting difference in the 328 
distribution of these two tumour locations compared with those in the Swiss Canine 329 
Cancer Registry. Tumours of bones, joints and joint cartilage were similar in ranking 330 
for all examination methods and post-mortem investigation, with 1.82% and 4.84%, 331 
respectively. As previously mentioned, the investigation method had a strong impact 332 
on the distribution percentage. Gamlen et al. (2008) describe tumours of bones, 333 
joints and joint cartilage as comparatively rare, with rates below 1.00%. Oral tumours 334 
amounted to 1.24% of all tumours. Vascellari et al. (2009) found oral tumours more 335 
than twice as frequently in dogs in Northern Italy (2.6%) and Gamlem et al. (2008) 336 
even more in dogs in Norway (3.7%). This discrepancy might be due to different 337 
sampling strategies. In the Swiss Canine Cancer Registry post-mortem data and 338 
biopsy samples were used, whereas in the Italian and Norwegian data biopsy 339 
samples alone were used, where an overestimation of oral tumours might be 340 
expected. In accordance with the findings of Porello et al. (2006) and Thamm and 341 
Dow (2009) oral tumours represented the highest tumour type variety, including 342 
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epithelial, lymphatic, mesenchymal, skeletal and odontogenic tumours and 343 
melanomas. Further research on these tumours may offer important insights for 344 
multi-modality therapy in clinical investigations. For the development of new 345 
therapies it is advantageous that oral tumours are fast to develop and hardly 346 
restrained by surgery alone (Porello et al., 2006).  347 
Adenoma and adenocarcinoma were the most frequent tumours in the Swiss Canine 348 
Cancer Registry, in concordance with the Tulsa Registry (MacVean et al., 1978). In 349 
the Danish Veterinary Cancer Registry the most frequently observed tumours were 350 
lipoma and adenoma (Brønden et al., 2010). Another study reported histiocytoma, 351 
lipoma and adenoma as the most frequent neoplasia (Dobson, 2013). The assigned 352 
tumour groups, however, are not always consistent, so comparison provides a rough 353 
overview only. 354 
We hope that this study marks the beginning of a continuous registration of dog 355 
tumours in Switzerland, which will serve as reference for research in the fields of 356 
animal and human oncology. To be able to compare results of different registries in 357 
the future it is important that data collection is assimilated with other dog registries as 358 
it is for human registries.  359 
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Table 1: Coding and grading of tumour diagnoses according to ICD-O-3. 
Diagnosis ICD-O code 
Odontogenic neoplasia ICD-O 9270 - 9330 
Trophoblastic tumours ICD-O 9104 
Epithelial tumour 
ICD-O 8010 - 8587, 
ICD-O 9050 - 9058 
Germ cell tumour ICD-O 9060 - 9085 
Lymphangioma, 
lymphangiosarcoma 
ICD-O 9590 - 9960 
Lymphatic tumour ICD-O 9590 - 9960 
Melanoma ICD-O 8720 - 8730 
Mesenchymal tumour 
ICD-O 8680 - 8711, 
ICD-O 8800 - 9040, 
ICD-O 9120 - 9150, 
ICD-O 9580 
Skeletal tumour ICD-O 9180 - 9262 
Neural tumour ICD-O 9380 - 9570 
Special gonadal neoplasia ICD-O 8610 - 8670 
Unspecified tumours ICD-O 8000 
 
Table 2: Coding of tumour locations according to ICD-O-3. 
Location ICD-O C code 
Blood, haematopoietic system  ICD-O C 42 
Neoplasia of bones, joints, cartilage  ICD-O C 40 – 41   
Brain, meninges, other parts of CNS ICD-O C 70 - 72 
Mammary gland  ICD-O C 50 
Endocrine gland  ICD-O C 73 - 75 
Gastrointestinal tract  ICD-O C 16 - 26.8 
Lymph nodes  ICD-O C 77 
Male sexual organs  ICD-O C 60 - 63.2 
Oral cavity, pharynx  ICD-O C 2.9 - 11 
Other female sex organs  ICD-O C 51 - 58 
Peripheral nerves, autonomic nervous system  ICD-O C 47 
Respiratory system, intrathoracic organs  ICD-O C 30 - 39 
Retroperitoneum, peritoneum  ICD-O C 48 
Skin  ICD-O C 44 
Soft tissues  ICD-O C 49 
Urinary organs  ICD-O C 67 - 68 
 
Table 3: Example of tumour grouping for four selected groups. 
Diagnosis group Single diagnosis Number 
Percentage 
[%] 
Table
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Skeletal tumour 
ICD-O 9180 - 9262 
Adamantinoma of long 
bones 103 8.7 
Chondroblastoma 22 1.86 
Chondroma, 
fibrochondrosarcoma 168 14.19 
Osteochondroma 11 0.93 
Osteofibroma 38 3.21 
Osteoma, osteosarcoma 842 71.11 
Total of skeletal tumours 1,184 100 
Special gonadal 
neoplasia ICD-O 
8610 - 8670 
Granulosa cell tumour, 
granulosa cell carcinoma 93 8.72 
Leydig cell tumour 450 42.17 
Luteoma 9 0.84 
Sertoli cell adenoma, 
sertoli cell carcinoma 423 39.64 
Sertoli-Leydig cell tumour 92 8.62 
Total of special gonadal neoplasia 1,067 100 
Gonadal germ cell 
tumour ICD-O 
9060-9085 
Embryonal carcinoma 3 0.45 
Seminoma 632 95.47 
Teratoma 8 1.21 
Germ cell tumours 19 2.87 
Total of germ cell tumours 662 100 
Epithelial tumour 
ICD-O 8010 - 8587, 
ICD-O 9050-9058 
Adenocarcinoma of anal 
glands 2,421 9.27 
Adenocarcinoma with 
squamous metaplasia 190 0.73 
Adenoma, 
Adenocarcinoma 12,348 47.27 
Adenomatous polyp, 
adenocarcinoma in 
adenomatous polyp  321 1.23 
Adrenal cortical adenoma, 
adrenal cortical 
adenocarinoma 168 0.64 
Basal cell carcinoma, 
adenoma 499 1.91 
Carcinoma, anaplastic 
type 296 1.13 
Cholangioma, 
cholangiocarcinoma 48 0.18 
Composite carcinoid 43 0.16 
Epithelial* tumour ICD-O 
8010 – 9053 1,677 6.42 
Epithelioid mesothelioma 37 0.14 
Epithelioma 958 3.67 
Hepatoma, 
hepatocarcinoma 155 0.59 
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Insulinoma 52 0.2 
Intracystic papillary 
adenoma, intracystic 
papillary adenocarcinoma 79 0.3 
Intraductal papilloma, 
intraductal papi 12 0.05 
Mesothelioma, biphasic, 
malignant 42 0.16 
Multifocal superficial basal 
cell carcinoma 231 0.88 
Papillary adenoma, 
adenocarcinoma 112 0.43 
Papillary carcinoma 871 3.33 
Pilomatrixoma 503 1.93 
Pulmonary adenomatosis, 
bronchiolo-alveolar 
adenocarcinoma 45 0.17 
Sebaceous adenoma, 
sebaceous 
adenocarcinoma 1,456 5.57 
Secretory carcinoma of 
the mammary gland 329 1.26 
Spindle cell carcinoma 72 0.28 
Squamous cell carcinoma 1,324 5.07 
Squamous papillomatosis 10 0.04 
Sweat gland adenoma, 
sweat gland 
adenocarcinoma 427 1.63 
Thymoma 96 0.37 
Transitional cell papilloma, 
transitional cell carcinoma 168 0.64 
Trichoepithelioma 1,132 4.33 
Total of epithelial tumours 26,122 100 
 
Table 4: The 17 most common canine breeds out of a total of 183 canine breeds among 121 963 canine 
patients. 
Canine breed Number Percentage [%] 
Shepherd 12,354 10.13% 
Crossbreed 12,193 10.00% 
Retriever 11,429 9.37% 
Swiss Mountain Dog 7,774 6.37% 
Poodle 7,214 5.91% 
Dachshund 6,499 5.33% 
Boxer 6,368 5.22% 
Schnauzer 2,796 2.29% 
Collie 2,206 1.81% 
Yorkshire Terrier 2,157 1.77% 
Cocker Spaniel 2,127 1.74% 
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Setter 2,105 1.73% 
Great Dane 1,598 1.31% 
Doberman Pinscher 1,596 1.31% 
Rottweiler 1,470 1.21% 
West Highland White Terrier 1,316 1.08% 
Bulldog 1,016 0.83% 
Parson Jack Russell Terrier 981 0.80% 
Other breeds (including dogs 
of unknown breed) 38,764 31.78% 
Total of all breeds 121,963 100% 
 
  
Figure 1: The influence of examination methods on the annual tumour incidence rate (IR = number of 
tumours diagnosed per 100 000 dogs in the Swiss dog population). 
 
 
 
Figure 2 Detailed most common tumour diagnoses (>1% of n= 67 943).  
 
Figure
 
Figure 3: The yearly most prevalent tumour diagnoses. The percentage of a tumour type among all 
tumour types diagnosed per year. 
 
 
Figure 4: Absolute [n] and relative [%] distribution of the malignancy in tumour diagnoses. In this figure 
epithelial tumour includes ICD-O 8010 – 8587 and ICD-O 9050-9058. 
 
 
Figure 5: Distribution of tumour locations diagnosed by all examination methods. (n) = number of all 
samples. [%] = proportion of tumour location. 
 
 
Figure 6: Distribution of tumour locations diagnosed by post mortem investigation. (n) = number of post-
mortem samples. [%] = proportion of tumour location. 
 
 
Figure 7: Tumour location and diagnoses. (n) = number of tumours found in a location; [%] = proportion 
of the location compared to the total of locations. Figures in and around the slices = relative proportion of 
tumour diagnoses / location. Tumour diagnoses lower than 1% were added into “Other tumours”; 
locations lower than 1% and unclassified location were not listed. With the exception of “male sexual 
organs” the listed locations are not sex specific. 
 
 
Figure 8: Canine patients with none, one or several tumours per age. (n) = number of patients. 
 
 
Figure 9: Epithelial, mesenchymal and lymphatic tumours per age of patient. n = number of tumour types 
per age. 
 
 
Figure 10: Melanoma, special gonadal neoplasia and skeletal tumours per age of patient. n = number of 
tumour types per age. 
 
